2026年10月16日星期五
M
환우통감
글로벌 속보
[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet

Immunogenicity and protective efficacy of a recombinant HtsA-SLOdm fusion protein against Group A Streptococcus infection

출처 Nature 生命科学10시간 전
내용 요약

Immunogenicity and protective efficacy of a recombinant HtsA-SLOdm fusion protein against Group A Streptococcus infection

본 사이트는 제목과 요약 색인만 제공하며, 전체 내용과 저작권은 모두 원 발행처에 있습니다. 원문 링크를 클릭하여 읽어 주세요.

원문 보기
소속 채널
과학
소속 지역
글로벌 시각
원문 언어
English
항목 번호
science-d1884f7a

Comments 0 comments

No comments yet. Be the first.

Immunogenicity and protective efficacy of a recombinant HtsA-SLOdm fusion protein against Group A Streptococcus infection · 환우통감